or Try an Advanced Search...

    Technical Analysis for PTCT - PTC Therapeutics, Inc.

    Grade Last Price % Change Price Change
    B 43.01 2.50% 1.05
    PTCT closed up 6.61 percent on Wednesday, November 20, 2024, on approximately normal volume. It was able to find support at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical PTCT trend table...
    Date Alert Name Type % Chg
    50 DMA Support Bullish 2.50%
    Crossed Above 20 DMA Bullish 2.50%
    Stochastic Buy Signal Bullish 2.50%
    Expansion Pivot Buy Setup Bullish Swing Setup 2.50%
    Wide Range Bar Range Expansion 2.50%
    Multiple of Ten Bullish Other 2.50%
    Outside Day Range Expansion 2.50%
    Oversold Stochastic Weakness 2.50%
    50 DMA Support Bullish 9.27%
    Multiple of Ten Bearish Other 9.27%
    Older End-of-Day Signals for PTCT ...

       Recent Intraday Alerts

    Alert Time
    Up 3% 42 minutes ago
    Up 2% about 1 hour ago
    Expansion Pivot Buy Entry about 3 hours ago
    Rose Above Previous Day's High about 3 hours ago
    60 Minute Opening Range Breakout about 3 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    PTCT Chart by TradingView
    Basic chart:

    Profile

    PTC Therapeutics, Inc. Description

    PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and proprietary small-molecule drugs for patients living with serious and life-threatening conditions, including genetic and neuromuscular disorders, cancer, and infectious diseases. Its approach includes post-transcriptional control, RNA biology, and gene expression modulation by small-molecules. The company has strategic alliances with AstraZeneca; Celgene Corporation; Cystic Fibrosis Foundation; Genzyme Corporation; Gilead; Muscular Dystrophy Association; Merck & Co., Inc.; Parent Project Muscular Dystrophy; Pfizer Inc.; Roche; Spinal Muscular Atrophy Foundation; and Wellcome Trust. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Biology Infectious Diseases Neurological Disorders Dystrophy Gene Expression Muscular Dystrophy Cystic Fibrosis Neurodegenerative Disorders Transcription Spinal Muscular Atrophy Genzyme Neuromuscular Disorders

    Is PTCT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 5 bullish, 0 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 14 FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain
    Nov 14 FDA grants accelerated approval for PTC’s AADC deficiency gene therapy
    Nov 14 PTC Therapeutics wins FDA nod for gene therapy
    Nov 14 PTC wins US approval of gene therapy for fatal enzyme disorder
    Nov 13 PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy
    Nov 9 PTC Therapeutics Third Quarter 2024 Earnings: Beats Expectations
    Nov 8 JFrog slips as earnings season hops along while pair of semis rebound
    Nov 8 PTC Therapeutics Inc (PTCT) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...
    Nov 8 PTC Therapeutics, Inc. (PTCT) Q3 2024 Earnings Call Transcript
    Nov 7 PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
    See more PTCT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 46.98
    52 Week Low 20.745
    Average Volume 772,051
    200-Day Moving Average 33.43
    50-Day Moving Average 38.91
    20-Day Moving Average 41.68
    10-Day Moving Average 42.29
    Average True Range 2.20
    RSI (14) 54.34
    ADX 30.37
    +DI 31.09
    -DI 19.48
    Chandelier Exit (Long, 3 ATRs) 40.39
    Chandelier Exit (Short, 3 ATRs) 44.77
    Upper Bollinger Bands 45.25
    Lower Bollinger Band 38.10
    Percent B (%b) 0.54
    BandWidth 17.16
    MACD Line 0.63
    MACD Signal Line 1.09
    MACD Histogram -0.4574
    Fundamentals Value
    Market Cap 3.17 Billion
    Num Shares 75.5 Million
    EPS -8.82
    Price-to-Earnings (P/E) Ratio -4.76
    Price-to-Sales 2.45
    Price-to-Book 1743.27
    PEG Ratio 0.81
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 48.75
    Resistance 3 (R3) 48.28 45.53 47.62
    Resistance 2 (R2) 45.53 43.80 45.77 47.24
    Resistance 1 (R1) 43.75 42.73 44.64 44.22 46.87
    Pivot Point 41.00 41.00 41.45 41.24 41.00
    Support 1 (S1) 39.22 39.27 40.11 39.70 37.05
    Support 2 (S2) 36.47 38.20 36.71 36.68
    Support 3 (S3) 34.69 36.47 36.30
    Support 4 (S4) 35.17